Which has the lower trailing P/E, HSTM or PCRX?

HSTM has the lower trailing P/E: HSTM trades at 43.64 and PCRX at 70.22. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, HSTM or PCRX?

Over the past five years, PCRX grew revenue faster — HSTM at a 5.05% CAGR versus PCRX at 8.20%.

Does HSTM or PCRX pay a bigger dividend?

HSTM pays a dividend (0.43% yield), while PCRX has no payments in the available dividend history.

Is HSTM or PCRX more profitable?

HSTM runs the higher net margin — HSTM at 6.60% versus PCRX at 1.96%.

How have HSTM and PCRX total returns compared?

Over the past 10 years, HSTM delivered 1.25% and PCRX delivered -3.60% annualized total return. Past performance doesn't predict future results.

HealthStream, Inc. (HSTM) vs Pacira BioSciences, Inc. (PCRX)

A side-by-side comparison of HealthStream, Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

HSTM

HealthStream, Inc.

$912M

$31.22HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

PCRX

Pacira BioSciences, Inc.

$970M

$24.67HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — HSTM vs PCRX

growth of $100 · dividends reinvested · last 10y

HSTM +16.2% (+1.5%/yr)PCRX -27.9% (-3.2%/yr)HSTM compounded faster over this window

HSTM PCRX

HSTM vs PCRX: by the numbers

•PCRX is the larger company ($970M vs $912M market cap).
•HSTM trades at the lower trailing earnings multiple (43.64 vs 70.22 P/E), one valuation lens rather than an overall verdict.
•HSTM converts more revenue to profit (6.60% vs 1.96% net margin).
•PCRX grew revenue faster over the past five years (8.20% vs 5.05% CAGR).
•HSTM pays a dividend (0.43% yield), while PCRX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	HSTM	PCRX
P/E ratio	43.64	70.22
Forward P/E	42.30	N/A
PEG ratio	6.47	N/A
P/S ratio	2.84	1.30
P/B ratio	2.56	1.44
EV / EBITDA	12.51	11.36
FCF yield	5.36%	18.50%

Profitability

Metric	HSTM	PCRX
Gross margin	65.08%	79.21%
Operating margin	8.04%	2.47%
Net margin	6.60%	1.96%
ROE	5.94%	2.18%
ROIC	4.96%	1.35%

Dividends

Metric	HSTM	PCRX
Dividend yield	0.43%	N/A
Payout ratio	19.01%	N/A

Growth (annualized)

Metric	HSTM	PCRX
Revenue CAGR (5Y)	5.05%	8.20%
EPS CAGR (5Y)	6.75%	-45.77%
FCF CAGR (5Y)	2.33%	16.72%
Total return CAGR (5Y)	2.34%	-12.27%

Frequently asked

Which has the lower trailing P/E, HSTM or PCRX?: HSTM has the lower trailing P/E: HSTM trades at 43.64 and PCRX at 70.22. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, HSTM or PCRX?: Over the past five years, PCRX grew revenue faster — HSTM at a 5.05% CAGR versus PCRX at 8.20%.
Does HSTM or PCRX pay a bigger dividend?: HSTM pays a dividend (0.43% yield), while PCRX has no payments in the available dividend history.
Is HSTM or PCRX more profitable?: HSTM runs the higher net margin — HSTM at 6.60% versus PCRX at 1.96%.
How have HSTM and PCRX total returns compared?: Over the past 10 years, HSTM delivered 1.25% and PCRX delivered -3.60% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HSTM analysis Full PCRX analysis Interactive comparison tool

Dig into the metrics

HealthStream P/E ratio Pacira BioSciences P/E ratio HealthStream dividend yield HealthStream ROE Pacira BioSciences ROE HealthStream operating margin Pacira BioSciences operating margin HealthStream revenue growth Pacira BioSciences revenue growth HealthStream free cash flow Pacira BioSciences free cash flow

HealthStream & Pacira BioSciences appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.